Clinical Trials Logo

Relapsed Hodgkin Lymphoma clinical trials

View clinical trials related to Relapsed Hodgkin Lymphoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04134325 Recruiting - Clinical trials for Refractory Hodgkin Lymphoma

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Start date: September 1, 2019
Phase: Early Phase 1
Study type: Interventional

LCCC1852-ATL is a prospective 2-arm study designed to determine if chimeric antigen receptor T (CAR-T) cells result in immunomodulation which can be subsequently exploited by programmed cell death protein 1 (PD-1) antibodies to achieve clinical responses in subjects with relapsed/refractory (r/r) classical Hodgkin Lymphoma (cHL).